ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P 500
5,304.72
0.70%
US Tech 100
18,318.00
0.95%
Dow Jones
39,069.59
0.01%
Brent Oil
81.965
0.00%
Bitcoin
69,165.07
0.93%
Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. AcelRX Pharmaceuticals Inc (ACRX)

  7. AcelRX Pharmaceuticals Inc (ACRX) News

ACRX

AcelRX Pharmaceuticals (ACRX)

AcelRX Pharmaceuticals Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:ACRX
DateTimeSourceHeadlineSymbolCompany
04/29/20244:25PMEdgar (US Regulatory)Form ARS - Annual Report to Security HoldersNASDAQ:ACRXAcelRX Pharmaceuticals Inc
04/29/20244:24PMEdgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:ACRXAcelRX Pharmaceuticals Inc
04/29/20244:23PMEdgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:ACRXAcelRX Pharmaceuticals Inc
04/19/20244:37PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:ACRXAcelRX Pharmaceuticals Inc
03/21/20244:30PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ACRXAcelRX Pharmaceuticals Inc
03/15/20244:01PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ACRXAcelRX Pharmaceuticals Inc
03/12/20246:39PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ACRXAcelRX Pharmaceuticals Inc
01/09/20249:17AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:ACRXAcelRX Pharmaceuticals Inc
01/09/20249:05AMPR Newswire (US)AcelRx Announces Rebranding With Name Change to Talphera, Inc.NASDAQ:ACRXAcelRX Pharmaceuticals Inc
12/14/20238:11AMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ACRXAcelRX Pharmaceuticals Inc
12/13/20234:34PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ACRXAcelRX Pharmaceuticals Inc
12/13/20234:25PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ACRXAcelRX Pharmaceuticals Inc
12/12/20238:30AMPR Newswire (US)AcelRx Pharmaceuticals Announces Publication of Study Evaluating Anticoagulation Practices for Continuous Renal Replacement Therapy in the United StatesNASDAQ:ACRXAcelRX Pharmaceuticals Inc
12/01/202312:15AMEdgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:ACRXAcelRX Pharmaceuticals Inc
11/22/20234:38PMEdgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:ACRXAcelRX Pharmaceuticals Inc
11/22/20234:34PMEdgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:ACRXAcelRX Pharmaceuticals Inc
11/14/20236:07AMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ACRXAcelRX Pharmaceuticals Inc
11/08/20234:14PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:ACRXAcelRX Pharmaceuticals Inc
11/08/20234:05PMPR Newswire (US)AcelRx Reports Third Quarter 2023 Financial Results and Provides Corporate UpdateNASDAQ:ACRXAcelRX Pharmaceuticals Inc
11/07/20234:05PMPR Newswire (US)AcelRx to Host KOL Panel Discussion on Current Anticoagulant Use in Dialysis and the Upcoming Niyad™ Clinical StudyNASDAQ:ACRXAcelRX Pharmaceuticals Inc
10/26/20234:30PMPR Newswire (US)AcelRx to Host Third Quarter 2023 Financial Results Call and Webcast on November 8, 2023NASDAQ:ACRXAcelRX Pharmaceuticals Inc
10/20/20234:30PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:ACRXAcelRX Pharmaceuticals Inc
10/10/20234:17PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:ACRXAcelRX Pharmaceuticals Inc
10/05/20234:45PMEdgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:ACRXAcelRX Pharmaceuticals Inc
10/05/20234:30PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:ACRXAcelRX Pharmaceuticals Inc
10/03/20238:30AMPR Newswire (US)AcelRx Receives IDE Approval for Niyad and Advances to a Single Registration StudyNASDAQ:ACRXAcelRX Pharmaceuticals Inc
09/22/20235:18PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:ACRXAcelRX Pharmaceuticals Inc
09/11/20237:13PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ACRXAcelRX Pharmaceuticals Inc
09/06/20238:30AMPR Newswire (US)AcelRx Pharmaceuticals to Participate in the H.C. Wainwright Annual Investment ConferenceNASDAQ:ACRXAcelRX Pharmaceuticals Inc
08/28/20236:35AMEdgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:ACRXAcelRX Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:ACRX

Your Recent History

BIT
P17RD5
BNP Paribas Issuance
AQSE
EVA
Evrima
BIT
I08077
Intesa Sanpaolo
BOV
CTKA4
KARSTEN PN
BIT
SAB
Sabaf
BIT
SHE
Shedir Pharma
BIT
SBB
Sababa Security
BIT
P13DB8
BNP Paribas Issuance
COIN
BXHETH
BXHToken
NASDAQ
NECXX
Nations Tax Exempt Reserves Inve
BOV
NVDC34
NVIDIA Corp DRN
BIT
I06021
Banca Imi
BIT
P1D9O0
BNP Paribas Issuance
BIT
P88130
Bnp Paribas Issuance
BOV
USSX34
United States Steel
BIT
DAL
Datalogic
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

United States
Company
Business
Popular
Get The App
App Store
Google Play

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved